Anthera Announces Fourth Quarter 2011 Financial Report and Conference Call
HAYWARD, Calif., Feb. 9, 2012 /PRNewswire/ — Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, will release its fourth quarter 2011 financial report before the market opens on Tuesday, February 21, 2012. Anthera will host a conference call at 1 pm Eastern Time in conjunction with the release. The Company will also provide an update for both the varespladib and blisibimod clinical programs.
Conference Call Access: Date: Tuesday, February 21, 2012 Time: 1:00 pm Eastern Time
Domestic Dial-in: (877) 312-8807 International Dial-in: (253) 237-1190 Conference ID: 47038854
To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406. The conference ID for the replay is 47038854. The audio replay will be available until February 28, 2012.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has three late stage clinical products: varespladib methyl (A-002), A-001 and blisibimod (A-623). Varespladib methyl (A-002) and A-001 are designed to inhibit a novel enzyme target known as secretory phospholipase A2 (sPLA2). Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. Blisibimod targets elevated levels of B-lymphocyte stimulator (BAFF), which have been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus) and rheumatoid arthritis.
CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., firstname.lastname@example.org or 510-856-5586.
SOURCE Anthera Pharmaceuticals, Inc.